Mariano Provencio Pulla

Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

BackgroundSavolitinib is an oral, potent, highly selective MET–tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)–TKI, has shown activity in patients with EGFR-mutated, advanced non–small-cell lung can...